Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients - Wikidata - wikimedia - TriplyDB

Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients

Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients

http://www.wikidata.org/entity/Q37067117

about

Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay Physiological effects and therapeutic potential of proinsulin C-peptide Anti-inflammatory properties of C-Peptide.Insulin therapy for pre-hyperglycemic beta-cell endoplasmic reticulum crowding.Type 1 diabetes: A predictable disease.The clinical potential of C-peptide replacement in type 1 diabetes.C-Peptide and vascular complications in type 2 diabetic subjects.Interaction between peroxisome proliferator- activated receptor gamma polymorphism and overweight on diabetic retinopathy in a Chinese case-control study.Factors determining insulin requirements in women with type 1 diabetes mellitus during pregnancy: a review The clinical utility of C-peptide measurement in the care of patients with diabetes The clinical measures associated with C-peptide decline in patients with type 1 diabetes over 15 years.Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents.Vitamin D Deficiency and Cardio-Metabolic Risk in a North Indian Community with Highly Prevalent Type 2 Diabetes Cardiac autonomic neuropathy in patients with diabetes mellitus.C-peptide is independent associated with diabetic peripheral neuropathy: a community-based study.C-peptide and long-term complications of diabetes.Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes?Painful and painless diabetic neuropathy: one disease or two?C-Peptide and its career from innocent bystander to active player in diabetic atherogenesis.The therapeutic potential of C-peptide in kidney disease: a protocol for a systematic review and meta-analysis.C-peptide antioxidant adaptive pathways in β cells and diabetes.The clinical potential of low-level C-peptide secretion.Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.Enhanced insulin action following subcutaneous co-administration of insulin and C-peptide in rats.Molecular effects of C-Peptide in microvascular blood flow regulation.Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease Efficacy of a long-acting C-peptide analogue against peripheral neuropathy in streptozotocin-diabetic mice.ω-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity Factors Associated with C-peptide Levels after Diagnosis in Children with Type 1 Diabetes Mellitus.Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients.Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study.C-peptide levels and the risk of diabetes and pre-diabetes among Chinese women with gestational diabetes.C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells.Early transcriptional regulation by C-peptide in freshly isolated rat proximal tubular cells.Implicações clínicas da persistência de anti-GAD positivo e peptídeo C detectável em pacientes com diabetes melito tipo 1 de longa duração Anemia is inversely associated with serum C-peptide concentrations in individuals with type 2 diabetes

P2860

Q24600478-950243A5-82DF-44C6-A3C5-8E47EA06AE86 Q27012286-5EFD16D9-9CCF-4F77-B568-274F72C219CC Q33682573-3BDF8905-F393-4ADC-83F7-422201380636 Q34585855-314871E3-4CCC-4DA0-BCFE-E728A50E76E0 Q35437721-3EED923D-B1C8-41D8-93C1-9B1D1DA55504 Q35857755-10388B71-4902-4A1F-8444-DFB17157FF12 Q36365226-F3F1788A-6325-473A-90F0-C68C132DF803 Q36493240-58BB10D0-DDA2-4BF1-93DE-81F60B6F33F3 Q37070253-FACED3C4-2038-4198-AD87-FBDD1334388E Q37108880-AE12A5BD-3E1D-4D9E-83FD-7E707C72BBC3 Q37147347-0DDE2CFF-14D5-4DD1-A67D-C30422E2AA2E Q37278130-413DC37E-936A-49E6-BEA0-EA3B5E3887C1 Q37279083-ECDA6720-E11A-476C-BCA4-9F91AD74E748 Q37598878-EEEA9B5F-720B-4FB6-A66B-E4D54B9C5F1D Q37640703-19AFD4E1-9AB3-476D-B10F-24F62540B86E Q37815562-162CFE07-622C-4498-A77C-9E309A65983C Q37940632-253E1B75-1CD4-4D68-8EC9-3EECAE71C845 Q38086802-CBBCB103-77DD-4D49-BB7B-6640792CCC19 Q38107138-AB97B977-F09D-41CF-B25B-30DD6F806657 Q38112357-B1B72890-9626-4500-ABF2-211CD9960DB0 Q38216760-9A5327BB-D90E-4F8A-81F6-1FC5432A2FA6 Q38850708-0C238FCD-7363-4B6C-BC9A-707B8503E8EB Q38889362-56A63FF5-23E0-4B69-AC95-242D6CD5F63D Q38927961-616358AD-1233-47A7-B6B8-DC896802388D Q39096910-ABC916B5-E25F-49D7-84D6-22C3F26B0F40 Q39224550-1AE8997B-FA53-43D5-BD20-520E1486E9DA Q39679120-13C3CE70-7DA9-4297-A556-AD05655E95FF Q41026519-D8D9A101-167F-4414-8AD6-E9EF782183D7 Q41880842-84AC017D-258F-4047-B90C-C617C323F785 Q42261993-96A2B503-8E23-4055-A889-2371305C5F08 Q43713192-839C6360-3BCA-4A22-9679-52D7DADD59D4 Q44916781-BC73B271-73E6-4378-8072-C8981326A458 Q50053135-18AE590F-2418-4C61-8952-AEEF0E71DAC4 Q53231716-7C0AFF5F-F175-4505-9FCB-76B86432A6B6 Q54369086-1748922F-B8F9-4493-BC81-BBE1EE63FBB2 Q57831167-64DDCDF2-5B02-4CED-9549-4E43A7B90380 Q58789121-157DACBA-C494-4DEC-9D32-4F75C81FDAF7

P2860

Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients

http://www.wikidata.org/entity/Q37067117

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Fasting plasma C-peptide and m ...... rt of type 1 diabetic patients

@en

Fasting plasma C-peptide and m ...... t of type 1 diabetic patients.

@nl

type

label

Fasting plasma C-peptide and m ...... rt of type 1 diabetic patients

@en

Fasting plasma C-peptide and m ...... t of type 1 diabetic patients.

@nl

prefLabel

Fasting plasma C-peptide and m ...... rt of type 1 diabetic patients

@en

Fasting plasma C-peptide and m ...... t of type 1 diabetic patients.

@nl

P1433

Q37067117-34133B5A-803E-4E37-B9DA-B200D043AEE0

P1476

Q37067117-8D8D9FDA-D364-4AB4-B566-005D1DF63FF7

P2093

Q37067117-17A89AA8-C3CB-4845-A352-E54142D3DEA3

Q37067117-4F9CA9E5-296F-476C-BC73-1797922F02C3

Q37067117-8717F60C-A02F-4DC8-9387-FA8761DA661D

Q37067117-9146BF7B-4365-4B61-BCF7-56380D4B1268

Q37067117-9660390F-BA4B-45FC-BDE0-0C0519CCF7F3

Q37067117-A3D6038E-0B21-4A1A-9318-D1DE08DF9894

Q37067117-A6F84818-183E-4891-BA52-7BA04F96E959

P2860

Q37067117-09B7624B-6BCF-485A-AE48-D7FC13DB09EA

Q37067117-187AFE4D-E6F3-4AEC-81C4-DBC1900AC0A3

Q37067117-21FC536B-291A-4EE4-AE49-A34ADD3151AB

Q37067117-339D116F-8D00-4D73-8BBA-54A16EBF1DAC

Q37067117-4E0119C0-E3CB-4430-9FFA-D196B568A8C2

Q37067117-55E40A18-D0C8-4B59-AFC3-B75574DFA8F6

Q37067117-5CBCFF3A-EE3E-40F1-99B1-6DE342689B0A

Q37067117-66CFE480-985C-48B2-BF4F-346E55FACE60

Q37067117-8D01AD10-705D-462C-8C72-B6C981365EA2

Q37067117-9504CF32-88C4-46AE-865A-6E805E152D00

P304

Q37067117-6055B658-9544-487F-A77C-F2AAB44EEB95

P31

Q37067117-430F0D01-32A9-4E74-B4AC-77DB7FA298C9

P356

Q37067117-3BE12C7A-1B0C-4226-9DF0-C7E445FB3D5F

P407

Q37067117-B5477744-B3F0-4E1F-A5D9-FE0EFEB9CD3D

P433

Q37067117-1DD3C145-740F-4617-98D7-B8A5B2FC54D7

P478

Q37067117-9E2E8230-E732-4508-8FCD-31866C9B3A3C

P50

Q37067117-505859B7-6774-4DF8-8A60-473F8B044854

Q37067117-CE8CA97F-D97D-445F-B465-E4B062FB025F

P577

Q37067117-66309611-A91D-444F-8144-6BA24E8AC43D

P5875

Q37067117-2D49B919-3372-49F6-AD09-01F497166432

P698

Q37067117-BBF0CB9E-870A-4D46-8B7F-08C8D4A9C7DE

P932

Q37067117-2C92EA9E-8799-406D-B217-AD02162637C2

P356

P1433

P1476

Fasting plasma C-peptide and m ...... rt of type 1 diabetic patients

@en

P2093

Chiara Zucco

http://www.w3.org/2001/XMLSchema#string

Francesco Panero

http://www.w3.org/2001/XMLSchema#string

Giulia Novelli

http://www.w3.org/2001/XMLSchema#string

Massimo Perotto

http://www.w3.org/2001/XMLSchema#string

Olivia Segre

http://www.w3.org/2001/XMLSchema#string

Paolo Cavallo-Perin

http://www.w3.org/2001/XMLSchema#string

Paolo Fornengo

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Role of C-peptide in human physiology.

Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway.

Natural history of beta-cell function in type 1 diabetes.

Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry.

Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus.

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition.

P304

301-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC08-1241

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Graziella Bruno

P577

2008-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23481994

http://www.w3.org/2001/XMLSchema#string

P698

19017769

http://www.w3.org/2001/XMLSchema#string

P932

2628697

http://www.w3.org/2001/XMLSchema#string